Comparison of the everolimus concentrations measured in whole blood with everolimus QMS or sirolimus CMIA

References

• Kirchner GI, Meier-Wiedenback I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004;43:83–95.
   PubMed Web of Science ®Google Scholar
• Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol. 2009;9:324–337.
   PubMed Web of Science ®Google Scholar
• Pignataro G, Capone D, Polichetti G, et al. Neuroprotective, immunosuppressant and antineoplastic properties of mTOR inhibitors: current and emerging therapeutic options. Curr Opin Pharmacol. 2011;11:378–394.
   PubMed Web of Science ®Google Scholar
• Crowe A, Bruelisauer A, Duerr L, et al. Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metab Dispos. 1999;27:627–632.
   PubMed Web of Science ®Google Scholar
• Bohler T, Waiser J, Budde K, et al. The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation. Transplant Proc. 1998;30:2195–2197.
   PubMed Web of Science ®Google Scholar
• Dunn C, Croom KF. Everolimus: a review of its use in renal and cardiac transplantation. Drugs. 2006;66:547–570.
   PubMed Web of Science ®Google Scholar
• Moes DJ, Press RR, den Hartigh J, et al. Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. Clin Pharmacokinet. 2012;51:467–480.
   PubMed Web of Science ®Google Scholar
• Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet. 2001;40:573–585.
   PubMed Web of Science ®Google Scholar
• Mabasa VH, Ensom MHH. The role of therapeutic monitoring of everolimus in solid organ transplantation. Ther Drug Monit. 2005;27:666–676.
   PubMed Web of Science ®Google Scholar
• Segarra I, Brazelton TR, Guterman N, et al. Development of a high-performance liquid chromatographic-electrospray mass spectrometric assay for the specific and sensitive quantification of the novel immunosuppressive macrolide 40-O-(2-hydroxyethyl)rapamycin. J Chromatogr B Biomed Sci Appl. 1998;720:179–187.
   PubMed Web of Science ®Google Scholar
• Taylor PJ, Franklin ME, Graham KS, et al. A HPLC-mass spectrometric method suitable for the therapeutic drug monitoring of everolimus. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;848:208–214.
   PubMed Web of Science ®Google Scholar
• Salm P, Warnholtz C, Boyd J, et al. Evaluation of a fluorescent polarization immunoassay for whole blood everolimus determination using samples from renal transplant recipients. Clin Biochem. 2006;39:732–738.
   PubMed Web of Science ®Google Scholar
• Sallustio BC, Noll BD, Morris RG. Comparison of blood sirolimus, tacrolimus and everolimus concentrations measured by LC-MS/MS, HPLC-UV and immunoassay methods. Clin Biochem. 2011;44:231–236.
   PubMed Web of Science ®Google Scholar
• Dasgupta A, Moreno V, Balark S, et al. Rapid estimation of whole blood everolimus concentrations using architect sirolimus immunoassay and mathematical equations: comparison with everolimus values determined by liquid chromatography/mass spectrometry. J Clin Lab Anal. 2011;25:207–211.
   PubMed Web of Science ®Google Scholar
• Hermida-Cadahia EF, Tutor JC. Determination of everolimus in blood samples from kidney and liver transplant recipients using the sirolimus chemiluminescence magnetic microparticle immunoassay (CMIA) on the Architect-i1000® system. Scand J Clin Lab Invest. 2012;72:180–183.
   PubMed Web of Science ®Google Scholar
• Dasgupta A, Davis B, Chow L. Evaluation of QMS everolimus assay using Hitachi 917 analyzer: comparison with liquid chromatography/mass spectrometry. Ther Drug Monit. 2011;33:149–154.
   PubMed Web of Science ®Google Scholar
• Shipkova M, Rapp S, Rigo-Bonnin R, et al. Therapeutic drug monitoring of everolimus: comparability of concentrations determined by 2 immunoassays and a liquid chromatography tandem mass spectrometry method. Ther Drug Monit. 2017;39:102–108.
   PubMed Web of Science ®Google Scholar
• Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry. Part III. J Clin Chem Clin Biochem. 1988;26:783–790.
   PubMedGoogle Scholar
• Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307–310.
   PubMed Web of Science ®Google Scholar
• Bilić-Zulle L. Comparison of methods: passing and bablok regression. Biochem Med (Zagreb). 2011;21:49–52.
   PubMed Web of Science ®Google Scholar
• Giavarina D. Understanding bland altman analysis. Biochem Med (Zagreb). 2015;25:141–151.
   PubMed Web of Science ®Google Scholar
• Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Int J Nurs Stud. 2010;47:931–936.
   Web of Science ®Google Scholar
• Pieri M, Miraglia N, Gentile A, et al. Quantification of sirolimus and everolimus by immunoassay techniques: test specificity and cross-reactivity evaluation. Int J Immunopathol Pharmacol. 2008;21:585–594.
   PubMed Web of Science ®Google Scholar
• Coentrão L, Carvalho C, Sampaio S, et al. Relationship between everolimus blood concentration assessed using the innuofluor certican fluorescence polarization immunoassay and the architect I system sirolimus chemiluminescent microparticle immunoassay. Transpl Proc. 2010;42:1867–1869.
   PubMed Web of Science ®Google Scholar
• Moes DJ, Press RR, de Fijter JW, et al. Liquid chromatography-tandem mass spectrometry outperforms fluorescence polarization immunoassay in monitoring everolimus therapy in renal transplantation. Ther Drug Monit. 2010;32:413–419.
   PubMed Web of Science ®Google Scholar
• Dasgupta A. Limitations of immunoassays used for therapeutic drug monitoring of immunosuppressants. In: Oellerich M, Dasgupta A, editors. Personalized immunosuppression in transplantation-role of biomarker monitoring and therapeutic drug monitoring. Amsterdam: Elsevier; 2016. p. 29–56.
   Google Scholar
• Shipkova M, Hesselink DA, Holt DW, et al. Therapeutic drug monitoring of everolimus: a consensus report. Ther Drug Monit. 2016;38:143–169.
   PubMed Web of Science ®Google Scholar